NCT04895709 2026-04-13
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
Bristol-Myers Squibb
Cedars-Sinai Medical Center
University of Chicago
University of Kansas Medical Center
Memgen, Inc.
St Vincent's Hospital, Sydney
Jina Pharmaceuticals Inc.
Henan Cancer Hospital